Partner Therapeutics acquires Sanofi's immunostimulant Leukine
Executive Summary
Recently launched Partner Therapeutics Inc. (PTx; oncology) has commenced operations by acquiring the immunostimulant Leukine (sargramostim) from Sanofi for an undisclosed sum.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice